This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revision | ||
home:translations:polish [06.11.2018] – [Tło i naukowe uzasadnienia dla terapii] sallieq | home:translations:polish [05.10.2019] – [Data] sallieq | ||
---|---|---|---|
Line 24: | Line 24: | ||
===== Tło i naukowe uzasadnienia dla terapii ===== | ===== Tło i naukowe uzasadnienia dla terapii ===== | ||
- | | + | |
- | + | < | |
- | + | * [[home: | |
+ | * [[home: | ||
+ | * [[home: | ||
+ | * [[home: | ||
+ | </ | ||
Marshall Protocol (MP) to nazwa terapii opracowanej przez prof. Trevor' | Marshall Protocol (MP) to nazwa terapii opracowanej przez prof. Trevor' | ||
Line 300: | Line 304: | ||
Pacjenci, którzy zatrzymują olmesartan kończą się ich zwrotu. | Pacjenci, którzy zatrzymują olmesartan kończą się ich zwrotu. | ||
+ | ===== Data ===== | ||
+ | |||
+ | [[home: | ||
+ | |||
+ | [[home: | ||
+ | |||
+ | ==== Response in 5 diagnoses ==== | ||
+ | |||
+ | | ||
+ | |||
+ | SUCCESS RATES: Over all success rate 66.32% Over all unsuccessful 13.77% Over all unsure 19.91% | ||
+ | |||
+ | Sarcoidosis success 75.8% | ||
+ | |||
+ | Chronic Fatigue Syndrome success 60.1% | ||
+ | |||
+ | Lyme disease success 66.9% | ||
+ | |||
+ | Rheumatoid arthritis success 69.2% | ||
+ | |||
+ | Fibromyalgia success 64.2% | ||
+ | All Other Th1 disease success 59.8% | ||
===== Notes and comments ===== | ===== Notes and comments ===== | ||